Shanghai Fosun Pharmaceutical Group Co Ltd (600196) — Capital Reinvestment Ratio
Shanghai Fosun Pharmaceutical Group Co Ltd (600196) has a Capital Reinvestment Ratio of 0.53x as of December 2025, meaning it reinvests 1% of its operating cash flow (CN¥2.40 Billion) in capital expenditures (CN¥1.28 Billion). See Shanghai Fosun Pharmaceutical Group Co L balance sheet independence to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Shanghai Fosun Pharmaceutical Group Co Ltd Capital Reinvestment Ratio (1998–2025)
This chart tracks Shanghai Fosun Pharmaceutical Group Co Ltd's Capital Reinvestment Ratio across 28 annual periods. Check total reinvestment intensity of Shanghai Fosun Pharmaceutical Group Co L to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Shanghai Fosun Pharmaceutical Group Co Ltd (1998–2025)
Year-by-year Capital Reinvestment Ratio for Shanghai Fosun Pharmaceutical Group Co Ltd from 1998 to 2025. For live market cap and broader valuation context, see Shanghai Fosun Pharmaceutical Group Co L market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.74x | CN¥6.01 Billion | CN¥4.45 Billion | ▼ -24.8% |
| 2024 | 0.99x | CN¥4.48 Billion | CN¥4.41 Billion | ▼ -19.5% |
| 2023 | 1.22x | CN¥4.36 Billion | CN¥5.34 Billion | ▼ -12.4% |
| 2022 | 1.40x | CN¥4.22 Billion | CN¥5.89 Billion | ▲ +10.9% |
| 2021 | 1.26x | CN¥3.95 Billion | CN¥4.97 Billion | ▼ -26.8% |
| 2020 | 1.72x | CN¥2.58 Billion | CN¥4.44 Billion | ▲ +39.9% |
| 2019 | 1.23x | CN¥3.22 Billion | CN¥3.96 Billion | ▲ +14.2% |
| 2018 | 1.08x | CN¥2.95 Billion | CN¥3.17 Billion | ▲ +27.9% |
| 2017 | 0.84x | CN¥2.58 Billion | CN¥2.17 Billion | ▼ -7.6% |
| 2016 | 0.91x | CN¥2.11 Billion | CN¥1.92 Billion | ▲ +19.5% |
| 2015 | 0.76x | CN¥1.62 Billion | CN¥1.24 Billion | ▼ -18.3% |
| 2014 | 0.93x | CN¥1.20 Billion | CN¥1.12 Billion | ▼ -9.3% |
| 2013 | 1.03x | CN¥1.01 Billion | CN¥1.04 Billion | ▼ -41.0% |
| 2012 | 1.74x | CN¥665.52 Million | CN¥1.16 Billion | ▼ -30.7% |
| 2011 | 2.52x | CN¥316.65 Million | CN¥796.83 Million | ▲ +50.9% |
| 2010 | 1.67x | CN¥203.36 Million | CN¥339.17 Million | ▲ +25.5% |
| 2009 | 1.33x | CN¥261.87 Million | CN¥348.07 Million | ▲ +47.1% |
| 2008 | 0.90x | CN¥233.04 Million | CN¥210.63 Million | ▼ -43.3% |
| 2007 | 1.59x | CN¥131.48 Million | CN¥209.71 Million | ▲ +10.6% |
| 2006 | 1.44x | CN¥184.91 Million | CN¥266.61 Million | ▲ +22.0% |
| 2005 | 1.18x | CN¥188.35 Million | CN¥222.60 Million | ▲ +18.2% |
| 2004 | 1.00x | CN¥205.10 Million | CN¥205.02 Million | ▼ -43.2% |
| 2003 | 1.76x | CN¥150.14 Million | CN¥264.05 Million | ▲ +29.2% |
| 2002 | 1.36x | CN¥102.47 Million | CN¥139.52 Million | ▼ -34.4% |
| 2001 | 2.08x | CN¥68.15 Million | CN¥141.51 Million | ▲ +127.0% |
| 2000 | 0.91x | CN¥138.43 Million | CN¥126.63 Million | ▼ -55.2% |
| 1999 | 2.04x | CN¥38.20 Million | CN¥77.99 Million | ▲ +160.1% |
| 1998 | 0.79x | CN¥66.55 Million | CN¥52.25 Million | — |